47 completed, 38 active not recruiting, 22 recruiting, 22 unknown. 88 Phase 2, 40 Phase 3, 34 Phase 1, 10 Not applicable, 2 Early Phase 1.
Follow Intensity-Modulated Radiotherapy: new trials by email Literature Review of Intensity-Modulated Radiotherapy trials Research Report on Intensity-Modulated Radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities | Phase 3 | Recruiting | SWOG Cancer Research Network | 296 | 2026-12-02 | 2026-10-13 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 298 | 2026-12-01 | 2026-10-27 |
| Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 214 | 2026-12-01 | 2026-10-29 |
| Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC Tislelizumab, Paclitaxel, Cisplatin (75 mg/m2) - HPV-unrelated Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 104 | 2026-09-01 | 2026-08-20 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-10-27 |
| Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma Becotatug Vedotin, Toripalimab, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 28 | 2026-04-20 | 2026-04-29 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-03-05 | 2026-03-16 |
| Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Anlotinib Hydrochloride Capsules, Gemcitabine (GEM), Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 412 | 2026-03-01 | 2026-02-03 |
| Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2) - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 418 | 2026-01-15 | 2026-01-28 |
| Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma Adebrelimab (PD-L1 inhibitor), Cisplatin (100mg/m2), Intensity-modulated radiotherapy - Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 516 | 2025-12-01 | 2025-11-20 |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer Biospecimen Collection, Brachytherapy, Carboplatin - Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2025-11-05 | 2026-10-28 |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy - Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-07-30 | 2026-10-21 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. QL1706, Gemcitabine, Cisplatin - Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Recruiting | Sun Yat-Sen University Cancer Center | 580 | 2025-05-04 | 2025-05-22 |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma | Phase 3 | Suspended | National Cancer Institute (NCI) | 420 | 2025-02-18 | 2026-10-20 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection - Basal Ganglia Germinoma, Diabetes Insipidus | Phase 2 | Recruiting | Children's Oncology Group | 240 | 2024-10-22 | 2026-08-25 |
| Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study Intensity-modulated radiotherapy, Immunotherapy Therapy - Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Enrolling by invitation | Zhongnan Hospital | 25 | 2024-08-08 | 2025-03-24 |
Showing 20 of 158. Sign in to see all of them.
Nasopharyngeal Carcinoma (22) · Squamous Cell Carcinoma of Head and Neck (18) · Nasopharyngeal Neoplasms (10) · Glioblastoma (9) · Oropharyngeal Neoplasms (9) · Gliosarcoma (8) · Carcinoma (7) · Esophageal Squamous Cell Carcinoma (7) · Head and Neck Neoplasms (7) · Hypopharyngeal Neoplasms (7) · Laryngeal Neoplasms (7) · Rectal Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Mouth Neoplasms (6) · Prostatic Neoplasms (6)
National Cancer Institute (NCI) (31) · Sun Yat-sen University (24) · NRG Oncology (13) · M.D. Anderson Cancer Center (10) · Mayo Clinic (7) · City of Hope Medical Center (6) · ECOG-ACRIN Cancer Research Group (5) · Albert Einstein College of Medicine (4) · Children's Oncology Group (3) · Chinese Academy of Medical Sciences (3) · OHSU Knight Cancer Institute (3) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (3) · Emory University (2) · Fudan University (2) · GOG Foundation (2)
United States (103) · China (42) · Canada (25) · Australia (5) · Puerto Rico (5) · Hong Kong (4) · Israel (3) · Japan (3) · Saudi Arabia (3) · India (2) · Ireland (2) · South Korea (2) · Belgium (1) · Netherlands (1) · New Zealand (1)
Jun Ma, M.D. (5) · Fang-Yun Xie, M.D. (3) · Guopei Zhu, M.D. (3) · Steven H Lin (3) · Loren K Mell (2) · Mian Xi, MD (2) · Nabil F Saba (2) · Akila Viswanathan (1) · Akiva Novetsky, MD (1) · Alejandro Sanchez (1) · Amol M Takalkar, MD, MS, MBA, FACNM (1) · Andreas Rimner, MD (1) · Andrew J Hope (1) · Andrew Poklepovic, MD (1) · Andy M. Trotti, MD (1)
PMID 36990609, PMID 28837405, PMID 29584545, PMID 31150573, PMID 35355438, PMID 22178121, PMID 24309981, PMID 24552317, PMID 25057165, PMID 25105369, PMID 25113840, PMID 25519706, PMID 25847373, PMID 26163437, PMID 27084653, PMID 27152857, PMID 27701653, PMID 28317872, PMID 29868473, PMID 30213452, PMID 30449625, PMID 30642373, PMID 30995174, PMID 31163012, PMID 31545689, PMID 31681600, PMID 31912685, PMID 31996395, PMID 32009149, PMID 32058845, PMID 32077891, PMID 32126267, PMID 32504550, PMID 32827353, PMID 33051340, PMID 33096027, PMID 33102224, PMID 33370024, PMID 33492986, PMID 33507809, PMID 33571520, PMID 33608212, PMID 33771703, PMID 33842889, PMID 34028986, PMID 34196693, PMID 34351356, PMID 34454674, PMID 34519801, PMID 34632876
U10CA180868 (27), U10CA021661 (9), U10CA180820 (8), P30CA013330 (4), U10CA180886 (4), U10CA027469 (3), U10CA098543 (3), UG1CA189867 (3), P01CA021239 (2), P30CA033572 (2), P30CA138292 (2), U19CA021239 (2), K12CA086913 (1), P30CA006516 (1), P30CA008748 (1)